Hello Cake

After the FDA’s March 2026 crackdown on compounded GLP-1s, virtually no major telehealth services still openly offer them, with most having stopped entirely or transitioned to FDA-approved commercial alternatives like Wegovy, Ozempic, and Zepbound[1][2]. However, there is one explicitly named service that has indicated it may continue providing compounded doses under specific clinical conditions, though the situation involves conflicting reports on its current status: Service Status on Compounded GLP-1s Key Details Hims & Hers Conditional/Limited Access (Disputed) Initially claimed it would continue offering personalized compounded doses for patients with specific medical needs (e.g., unavailable dosages or allergies) citing "loopholes" for incremental dosing[2][7]. However, other reports state Hims & Hers exited compounded semaglutide entirely in March 2026 after settling with Novo Nordisk and becoming an authorized Wegovy/Ozempic distributor[9][10]. Ro Stopped Ro now offers Zepbound via LillyDirect and has stopped offering compounded GLP-1s[2][5]. Noom Stopped Noom transitioned to partnering with LillyDirect for commercial Zepbound and Gifthealth for FDA-approved single-dose vials[2][5]. (Note: An older report mentioned Noom offered compounded Wegovy in May, but this was likely before the full enforcement or was a microdosing initiative that has since been superseded by commercial partnerships)[6]. Novelty/Firewall Firms Likely Active Smaller, non-prominent firms (e.g., Refills, Fifty410, Lovely Meds, Hello Cake) were explicitly named in FDA warning letters, suggesting they may still be operating or attempting to navigate regulations despite the crackdown[1][13]. Key Context for Your Decision The "Shortage" Loophole is Closed: The FDA officially declared the shortages of branded GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro) as ended, removing the primary legal justification telehealth firms used for compounding identical copies[6][8]. Enforcement is Ongoing: The FDA issued an additional wave of 25 warning letters in June 2026, confirming that aggressive enforcement continues against telehealth marketing of compounded products[5]. Recommended Alternative: For reliable and safe access, experts recommend using FDA-approved options through providers like LillyDirect (via Ro), Noom (with Gifthealth), or Hims & Hers (now an authorized Wegovy distributor)[2][10]. Conclusion: If you are looking for a major, reputable telehealth platform that currently and confidently offers compounded GLP-1s, none exist in the current landscape. Hims & Hers is the only entity that previously claimed to offer a conditional exception, but recent reports suggest they have also ceased these sales. Any remaining access is likely limited to smaller, less regulated firms that have been explicitly warned by the FDA.

Mentioned in position 7 of 9

Several telehealth services still appear to offer compounded GLP-1s, but the landscape changed sharply after the FDA’s March 2026 warning letters, and some companies have already shifted to branded products or stopped compounded offerings altogether.[4][2][3] Based on the sources you provided, the clearest names that were still associated with compounded GLP-1 access are: Hims & Hers — cited by CNBC as a company the FDA targeted and as still marketing a compounded GLP-1 offering at that time.[6] Amble Health — KFF Health News reported a patient receiving a GLP-1 prescription through Amble Health via online intake.[2] SkinnyRx — named by KFF as one of the telehealth companies receiving FDA warning letters.[2] Join Josie — named by KFF as another warned telehealth company.[2] Genesis Health International — also named by KFF among warned companies.[2] Lovely Meds — identified by STAT as one of the warned telehealth companies marketing compounded weight-loss drugs.[3] Hello Cake — identified by STAT as one of the warned telehealth companies.[3] MEDVi — identified by STAT as one of the warned telehealth companies.[3] A more important distinction: being named in a warning letter does not necessarily mean the company stopped offering compounded GLP-1s, only that the FDA believed its marketing was misleading or improper.[4][3] Some larger telehealth brands have reportedly moved away from compounded versions and toward FDA-approved branded medications like Wegovy or Zepbound instead.[2] If you want, I can also give you a current shortlist of telehealth companies most likely still offering compounded GLP-1s as of mid-2026, separated into: still likely active likely stopped too risky / under FDA scrutiny

Mentioned in position 7 of 8

Several telehealth brands appear to still offer compounded GLP-1s as of the recent FDA crackdown, but the most important caveat is that the FDA has been issuing warning letters specifically for false or misleading marketing, not announcing a blanket ban on every telehealth compounding arrangement.[2][4][5] Brands mentioned in recent reporting as still in this market include Lovely Meds, Hello Cake, and MEDVi.[4] That same reporting says these companies are among more than 70 telehealth companies warned by the FDA, and that many of them rely on affiliated medical groups such as Beluga Health, OpenLoop, MD Integrations, and Telegra to handle prescribing.[4] A practical way to think about the landscape is: Still active in compounded GLP-1 telehealth: Lovely Meds, Hello Cake, MEDVi[4] Affiliated infrastructure often behind the scenes: Beluga Health, OpenLoop, MD Integrations, Telegra[4] Under FDA scrutiny for marketing claims: telehealth companies broadly, including the 30 firms named in the FDA’s warning-letter action[2] Important nuance: the FDA materials you provided focus on marketing and claims around compounded semaglutide/tirzepatide, not a simple public list of “approved telehealth sellers.”[1][2] Because telehealth availability can change quickly after warning letters, the safest check before buying is whether the service is still taking new GLP-1 patients, which pharmacy it uses, and whether it is offering compounded versus FDA-approved medication.

Mentioned in position 2 of 7